CompletedNCT00212771

Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846)

This study evaluated the safety and effectiveness of asenapine for people with schizophrenia.

Medication studyAges 18+

The study in practice

Understand this study

This study evaluated the safety and effectiveness of asenapine for people with schizophrenia.

Listed age limits: from 18 years.

Study clarity

Study start dateSeptember 2004

Recruitment status: Completed
Enrollment listed in the registry: 440
Sponsor: Organon and Co
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: Not clearly listed
Age range: Over 18 Years
Official registry ID: NCT00212771
Official title: Show the full official title
Long-Term Efficacy and Safety Evaluation of Asenapine (10-20 mg/Day) in With Schizophrenia or Schizoaffective Disorder, in a Multicenter Trial Using (10-20 mg/Day) as a Control

Completed

Locations not listed

FAQ

What did researchers investigate?

This study evaluated the safety and effectiveness of asenapine for people with schizophrenia.

Who is behind this study?

The study sponsor is Organon and Co.

Did this study involve medication?

Yes. The study involved medication, including asenapine and olanzapine.

Who was this study for?

Listed age limits: from 18 years.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.